Estradiol News and Research RSS Feed - Estradiol News and Research

Estradiol is a sex hormone. Mislabelled the "female" hormone, it is also present in males; it represents the major estrogen in humans. Estradiol has not only a critical impact on reproductive and sexual functioning, but also affects other organs including the bones.
Simultaneous use of hormones and statins can protect women from heart disease after menopause

Simultaneous use of hormones and statins can protect women from heart disease after menopause

Hormones may not protect women from heart disease or stroke after menopause, but when combined with cholesterol-lowering statin drugs, they may help protect women from these killers, shows a population study from Sweden to be published in the April issue of Menopause, the journal of The North American Menopause Society. [More]
Comprehensive review of sex hormones' role in female reproductive tract

Comprehensive review of sex hormones' role in female reproductive tract

Charles R. Wira, PhD, and colleagues at Dartmouth's Geisel School of Medicine have presented a comprehensive review of the role of sex hormones in the geography of the female reproductive tract and evidence supporting a "window of vulnerability" to HIV and other sexually transmitted infections (STIs). [More]
Letrozole helps restore fertility in obese, infertile men

Letrozole helps restore fertility in obese, infertile men

A letrozole pill once a week restored fertility in obese, infertile men and led to their partners giving birth to two full-term, healthy babies, according to a new study from Canada. The results will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego. [More]
Serum testosterone may decline due to decreased sexual activity and desire in older men

Serum testosterone may decline due to decreased sexual activity and desire in older men

In older men, decreased sexual activity and desire, not erectile dysfunction, may cause serum testosterone to decline, a new study from Australia finds. The results will be presented Saturday March 7, at ENDO 2015, the annual meeting of the Endocrine Society, in San Diego. [More]
Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration. [More]
VagiCap improves quality of life, satisfaction for postmenopausal women with vulvar and vaginal atrophy

VagiCap improves quality of life, satisfaction for postmenopausal women with vulvar and vaginal atrophy

Newly released patient satisfaction survey results from a study of a novel investigational vaginal estrogen treatment show promise for improving quality of life and satisfaction for postmenopausal women who experience pain during sex and other symptoms associated with vulvar and vaginal atrophy (VVA). [More]

Large numbers of boys suffer from cognitive disabilities linked to lead than girls

A study recently published in the Journal of Environmental Health provides evidence the female hormones estrogen and estradiol may help ward off the effects of lead exposure for young girls, explaining why boys, in greater numbers than girls, are shown to suffer from the cognitive disabilities linked to lead. [More]
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. [More]
Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis. [More]
FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. [More]
Even men undergo hormonal changes on way to fatherhood, study finds

Even men undergo hormonal changes on way to fatherhood, study finds

Impending fatherhood can lower two hormones--testosterone and estradiol--for men, even before their babies are born, a new University of Michigan study found. [More]
Research outlines new model for measuring acceptability of contraceptive vaginal ring

Research outlines new model for measuring acceptability of contraceptive vaginal ring

The Population Council published new research in the November issue of the journal Contraception demonstrating that an investigational one-year contraceptive vaginal ring containing Nestorone and ethinyl estradiol was found to be highly acceptable among women enrolled in a Phase 3 clinical trial. [More]
Sensitive toxicity test aims to detect dangerous side effects in pharmaceutical development

Sensitive toxicity test aims to detect dangerous side effects in pharmaceutical development

Because of undetected toxicity problems, about a third of prescription drugs approved in the U.S. are withdrawn from the market or require added warning labels limiting their use. An exceptionally sensitive toxicity test invented at the University of Utah could make it possible to uncover more of these dangerous side effects early in pharmaceutical development so that fewer patients are given unsafe drugs. [More]
Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan Inc. today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe. [More]
Endocrine Society issues updated Clinical Practice Guideline on androgens in women

Endocrine Society issues updated Clinical Practice Guideline on androgens in women

The Endocrine Society today issued a Clinical Practice Guideline (CPG) advising against the use of testosterone therapy in healthy women. [More]
Epidurals and reduced postpartum depression: an interview with Dr. Zakowski

Epidurals and reduced postpartum depression: an interview with Dr. Zakowski

The “maternity blues”, which resolve within 10 days of giving birth, occurs in up to 80% of new moms. A major depressive episode, by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, is defined as having at least a 2-week period of persistent depressed mood ... [More]
Measuring levels of sex hormones in patients' blood may identify risk of sudden cardiac arrest

Measuring levels of sex hormones in patients' blood may identify risk of sudden cardiac arrest

Measuring the levels of sex hormones in patients' blood may identify patients likely to suffer a sudden cardiac arrest, a heart rhythm disorder that is fatal in 95 percent of patients. [More]
Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Aeterna Zentaris Inc. today announced a strategic co-promotion services agreement with ASCEND Therapeutics US, LLC. [More]
Research suggests effective role for natural steroid hormones in treating breast cancer

Research suggests effective role for natural steroid hormones in treating breast cancer

A new study supports a growing body of research suggesting a safe and effective role for natural steroid hormones in treating postmenopausal breast cancer, with fewer detrimental side effects and improved health profile than with standard anti-hormone therapies. [More]
Researchers explore brain estrogens to mitigate learning and memory problems

Researchers explore brain estrogens to mitigate learning and memory problems

New studies being launched by neurobiologist Luke Remage-Healey at the University of Massachusetts Amherst will investigate how estrogens produced in the brains of young birds enhance their ability to learn songs during a critical window during development. [More]
Advertisement
Advertisement